Alendronate and osteoporosis

Drug Discovery Today

Volumn 3, Issue 2, 1998, Pages 69-78

  Yates, A John ^a   Rodan, Gideon A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; ETIDRONIC ACID; IBANDRONIC ACID; INCADRONIC ACID; NERIDRONIC ACID; OLPADRONIC ACID; PAMIDRONIC ACID; PLACEBO; RISEDRONIC ACID; TILUDRONIC ACID;

BONE DENSITY; BONE MINERAL; DRUG EFFICACY; DRUG SAFETY; FRACTURE; HUMAN; OSTEOPOROSIS; REVIEW;

EID: 0032007570     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(97)01134-3     Document Type: Review

References (42)

1. 1 Van Beek, E. et al. (1996) J. Bone Miner. Res. 11, 1492-1497
2. 2 Sato, M. et al. (1991) J. Clin. Invest. 88, 2095-2105
3. 3 Lin, J.H. et al. (1992) Drug Metab. Dispos. 20, 473-478
4. 4 Lin, J.H. (1996) Bone 18, 75-85
5. 5 Rodan, G.A. and Fleisch, H.A. (1996) J. Clin. Invest. 97, 2692-2696
6. 6 Murakami, H. et al. (1997) Bone 20, 399-404
7. 7 Rogers, M.J. et al. (1995) Mol. Pharmacol. 47, 398-402
8. 8 Hughes, D.E. et al. (1995) J. Bone Miner. Res. 10, 1478-1487
9. 9 Luckman, S.P. et al. (1997) Bone 20 (4, Suppl.), Abstract P378
10. 10 Schmidt, A. et al. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 3068-3073
11. 11 Toolan, B.C. et al. (1992) J. Bone Miner. Res. 7, 1399-1406
12. 12 LaFage, M-H. et al. (1995) J. Clin. Invest. 95, 2127-2133
13. 13 Fratzl, P. et al. (1996) J. Bone Miner. Res. 11, 248-253
14. 14 Balena, R. et al. (1993) J. Clin. Invest. 92, 2577-2586
15. 15 Flora, L. et al. (1981) Metab. Bone Dis. Relat. Res. 3, 289-300
16. 16 Balena, R. et al. (1996) J. Pharmacol. Exp. Ther. 276, 277-283
17. 17 Peter, C.P. et al. (1996) J. Orthop. Res. 14, 74-79
18. 18 Consensus Development Conference: Diagnosis (1993) Am. J. Med. 94, 646-650
19. 19 Melton, L.J., III et al. (1992) J. Bone Miner. Res. 7, 1005-1010
20. 20 Chrischilles, E.A. et al. (1991) Arch. Intern. Med. 151, 2026-2032
21. 21 Melton, L.J. et al. (1993) J. Bone Miner. Res. 8, 1227-1233
22. 22 Cummings, S.R. et al. (1993) Lancet 341, 72-75
23. 23 The Writing Group for the PEPI Trial (1996) J. Am. Med. Assoc. 276, 1389-1396
24. 24 Barrett-Connor, E. (1992) Annu. Rev. Med. 43, 239-251
25. 25 Lindsay, R. et al. (1980) Lancet ii, 1151-1153
26. 26 Boyce, B.F. et al. (1984) Lancet i, 821-824
27. 27 Gibbs, C.J. et al. (1986) Br. Med. J. 292, 1227-1229
28. 28 Jowsey, J. et al. (1971) J. Lab. Clin. Med. 78, 574-581
29. 29 Heaney R.P. and Saville, P.D. (1976) Clin. Pharmacol. Ther. 20, 593-604
30. 30 Frost, H.M. (1979) Clin. Orthop. Relat. Res. 143, 227-244
31. 31 Storm, T. et al. (1990) New Engl. J. Med. 322, 1265-1271
32. 32 Harris, S.T. et al. (1993) Am. J Med. 95, 557-567
33. 33 Watts, N.B. et al. (1990) New Engl. J. Med. 323, 73-79
34. 34 Valkema, R. et al. (1989) Bone Miner. 5, 183-192
35. 35 Garnero, P. et al. (1994) J. Clin. Endocrinol. Metab. 79, 1693-1700
36. 36 Chesnut, C.H., III et al. (1995) Am. J. Med. 99, 144-152
37. 37 Liberman, U.A. et al. (1995) New Engl. J. Med. 333, 1437-1443
38. 38 Bone, H.G. et al. (1997) J. Clin. Endocrinol. Metab. 82, 265-274
39. 39 Chavassieux, P.M. et al. J. Clin. Invest. (in press)
40. 40 Black, D.M. et al. (1996) Lancet 348, 1535-1541
41. 41 Karpf, D.B. et al. (1997) J. Am. Med. Assoc. 277, 1159-1162
42. 42 Fleisch, H. (1997) Bisphosphonates in Bone Disease: From the Laboratory to the Patient (3rd edn), Parthenon Publishing